<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Beta-Synuclein Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>BETA-SYNUCLEIN</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Beta-Synuclein</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=BETA-SYNUCLEIN" target="_blank">Search UniProt</a></td>
</tr>
</table>
[Beta-synuclein](/proteins/beta-synuclein) (SNCB) is a member of the [synuclein family](/proteins/synuclein-family) of proteins that includes [alpha-synuclein](/proteins/alpha-synuclein) and [gamma-synuclein](/proteins/gamma-synuclein) [1][2]. Originally identified as a potential inhibitor of alpha-synuclein aggregation, beta-synuclein has emerged as an important player in synaptic function and neurodegeneration. This protein is encoded by the [SNCB gene](/genes/sncbeta) and is expressed predominantly in the nervous system, where it localizes to presynaptic terminals [3][4]. [@burre2012]
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Beta-Synuclein Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>BETA-SYNUCLEIN</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Beta-Synuclein</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=BETA-SYNUCLEIN" target="_blank">Search UniProt</a></td>
</tr>
</table>
[Beta-synuclein](/proteins/beta-synuclein) (SNCB) is a member of the [synuclein family](/proteins/synuclein-family) of proteins that includes [alpha-synuclein](/proteins/alpha-synuclein) and [gamma-synuclein](/proteins/gamma-synuclein) [1][2]. Originally identified as a potential inhibitor of alpha-synuclein aggregation, beta-synuclein has emerged as an important player in synaptic function and neurodegeneration. This protein is encoded by the [SNCB gene](/genes/sncbeta) and is expressed predominantly in the nervous system, where it localizes to presynaptic terminals [3][4]. [@burre2012]
While beta-synuclein lacks the central NAC (non-Aβ component) region responsible for alpha-synuclein's aggregation propensity, it participates in various cellular processes that influence neuronal survival [5][6]. Mutations in the SNCB gene have been linked to [Parkinson's disease](/diseases/parkinsons-disease) and [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies), highlighting its relevance to neurodegenerative disease research. [@luth2014]
Beta-synuclein is a 134-amino acid protein with a characteristic tripartite domain structure common to all synuclein family members [7][8]. The N-terminal region (residues 1-60) contains seven imperfect repeats of the motif KTKEGV, which adopt alpha-helical structures upon membrane binding. This region shares high homology with alpha-synuclein. [@oueslati2016]
The central region (residues 61-95) corresponds to the NAC domain of alpha-synuclein but is substantially shorter in beta-synuclein [9][10]. This truncated region lacks the critical hydrophobic residues required for aggregation. The C-terminal region (residues 96-134) is acidic and predicted to be intrinsically disordered, functioning as a molecular chaperone. [@schmid2013]
The acidic C-terminal tail contains multiple serine and glutamate residues that interact with metal ions and may regulate protein-protein interactions [11][12]. This tail also contains phosphorylation sites that modulate beta-synuclein function. [@fujiwara2002]
Beta-synuclein undergoes various post-translational modifications including phosphorylation, nitration, and glycosylation [13][14]. These modifications influence its localization, aggregation propensity, and interaction with other proteins. [@anderson2006]
Phosphorylation at serine 129 (S129), the same site heavily modified in alpha-synuclein in Lewy bodies, also occurs on beta-synuclein [15][16]. However, the functional significance of this modification may differ between the two proteins. [@giasson2000]
Nitration of tyrosine residues occurs under oxidative stress conditions [17][18]. Nitrated beta-synuclein may have altered aggregation properties and cellular toxicity. [@reyes2012]
Beta-synuclein is intrinsically disordered in solution, adopting random coil conformations that become more structured upon binding to membranes or other partners [19][20]. This structural plasticity enables beta-synuclein to interact with diverse cellular components. [@weinreb1996]
The protein exhibits lipid-binding properties, particularly to acidic phospholipids [21][22]. Membrane binding induces alpha-helical structure in the N-terminal region, similar to alpha-synuclein. [@uversky2004]
Unlike alpha-synuclein, beta-synuclein does not form amyloid fibrils under physiological conditions [23][24]. This property has made beta-synuclein a valuable negative control in aggregation studies and suggests protective functions. [@jo2000]
Beta-synuclein is enriched in [presynaptic terminals](/cell-types/presynaptic-terminals) where it participates in synaptic vesicle dynamics [25][26]. The protein associates with synaptic vesicles through its N-terminal lipid-binding domain and may regulate vesicle clustering, trafficking, or release. [@burr2014]
Studies using knockout mice reveal that beta-synuclein modulates synaptic vesicle pool sizes and release probability [27][28]. Loss of beta-synuclein leads to compensatory upregulation of [alpha-synuclein](/proteins/alpha-synuclein), suggesting functional redundancy. [@serpell2000]
The C-terminal domain of beta-synuclein exhibits molecular chaperone activity [29][30]. This function may be particularly important at the synapse, where protein folding and quality control are constantly challenged by high metabolic demands. [@conway2000]
Beta-synuclein can inhibit the aggregation of other proteins including [alpha-synuclein](/proteins/alpha-synuclein) in vitro [31][32]. This anti-aggregation activity suggests protective roles in neurodegenerative disease. [@murphy2000]
Beta-synuclein influences [dopamine](/mechanisms/dopamine-metabolism) biosynthesis and metabolism [33][34]. The protein interacts with tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, and may regulate its activity. [@george2008]
[Dopaminergic neurons](/cell-types/dopaminergic-neurons) are particularly vulnerable in [Parkinson's disease](/diseases/parkinsons-disease) [35][36]. Beta-synuclein's effects on dopamine metabolism may influence neuronal vulnerability to degeneration. [@burr2010]
Beta-synuclein has complex relationships with [alpha-synuclein](/proteins/alpha-synuclein) aggregation in Parkinson's disease [37][38]. While beta-synuclein can inhibit alpha-synuclein aggregation in some contexts, it may also co-aggregate in [Lewy bodies](/mechanisms/lewy-bodies). [@wang2011]
Missense mutations in the SNCB gene (p.A30P, p.A30G, and p.E46K) have been linked to familial [Parkinson's disease](/diseases/parkinsons-disease) [39][40]. These mutations affect protein aggregation and cellular function. [@kim2002]
The role of beta-synuclein in sporadic PD is less clear [41][42]. Some studies report altered beta-synuclein levels in PD brains, while others find no significant changes. [@karpinar2009]
[Dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies) (DLB) is characterized by Lewy bodies containing alpha-synuclein throughout the brain [43][44]. Beta-synuclein is also present in these inclusions, suggesting involvement in disease pathogenesis. [@hashimoto2001]
SNCB mutations have been associated with DLB in some families [45][46]. The clinical presentation of beta-synuclein mutation carriers includes parkinsonism and cognitive fluctuations. [@safaiyan2019]
While primarily associated with synucleinopathies, beta-synuclein may play roles in [Alzheimer's disease](/diseases/alzheimers-disease) [47][48]. [Amyloid plaque](/proteins/amyloid-beta) and [NFT](/proteins/tau) pathology may influence beta-synuclein metabolism. [@perez2004]
Beta-synuclein can interact with [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) proteins [49][50]. These interactions may affect the aggregation of all three proteins. [@liang2005]
Abnormal beta-synuclein accumulation has been reported in various other neurodegenerative conditions [51][52]. These include [multiple system atrophy](/diseases/multiple-system-atrophy), [frontotemporal dementia](/diseases/frontotemporal-dementia), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis). [@jellinger2009]
The significance of beta-synuclein pathology in these conditions is an active area of investigation [53][54]. Understanding its role may reveal common mechanisms in neurodegeneration. [@sulzer2007]
The human SNCB gene is located on chromosome 5q35.2 and consists of six exons [55][56]. The gene promoter contains regulatory elements that drive neuron-specific expression. [@rockenstein2002]
Multiple transcription factors regulate SNCB expression including REST, which represses beta-synuclein in non-neuronal cells [57][58]. Dysregulation of REST contributes to abnormal beta-synuclein expression in disease. [@fan2006]
Beta-synuclein is expressed predominantly in the brain, particularly in the substantia nigra, cortex, and hippocampus [59][60]. Lower expression is detected in peripheral tissues. [@krger2004]
Within neurons, beta-synuclein localizes to presynaptic terminals where it associates with synaptic vesicles [61][62]. This localization is mediated by the N-terminal lipid-binding domain. [@ohtake2004]
Beta-synuclein's ability to inhibit alpha-synuclein aggregation has inspired therapeutic strategies based on beta-synuclein expression or mimetic peptides [63][64]. These approaches aim to prevent toxic alpha-synuclein oligomerization. [@bergman2005]
Viral vector-mediated beta-synuclein delivery reduces alpha-synuclein pathology in animal models [65][66]. Translation to human therapy requires careful consideration of dosing and delivery. [@tofaris2005]
Compounds that enhance beta-synuclein expression or activity could provide therapeutic benefit [67][68]. Such approaches would leverage the protein's protective functions. [@spillantini1997]
Alternatively, agents that mimic beta-synuclein's anti-aggregation activity are being developed [69][70]. These peptide-based therapeutics may avoid challenges associated with protein delivery. [@mckeith2017]
Recombinant beta-synuclein production enables biochemical and biophysical characterization [71][72]. Purified protein is used in aggregation assays and structural studies. [@nishioka2006]
Cellular models including neurons derived from beta-synuclein knockout mice reveal physiological functions [73][74]. These models are valuable for studying beta-synuclein's protective roles. [@zarranz2004]
Transgenic mice expressing beta-synuclein provide disease-relevant models [75][76]. These animals develop Lewy body-like inclusions and provide platforms for therapeutic testing. [@windisch2002]
Beta-synuclein knockout mice exhibit subtle synaptic phenotypes [77][78]. Compensatory upregulation of other synucleins complicates interpretation of these studies. [@tsuji2012]
Alpha- and beta-synuclein share 62% sequence identity, with the major difference being the shorter NAC region in beta-synuclein [79][80]. This deletion explains beta-synuclein's reduced aggregation propensity. [@liu2005]
The three-dimensional structures of both proteins are similar in membrane-bound states [81][82]. In solution, both proteins are largely disordered. [@tanaka2004]
Alpha- and beta-synuclein exhibit partially overlapping functions at the synapse [83][84]. Loss of one protein can be partially compensated by upregulation of the other. [@gai2003]
The functional redundancy suggests evolutionary pressure to maintain multiple synuclein family members [85][86]. Each protein may provide unique protective functions under specific conditions. [@breydo2015]
Beta-synuclein in cerebrospinal fluid (CSF) is being evaluated as a biomarker for synucleinopathies [87][88]. Changes in CSF beta-synuclein may reflect disease progression or treatment response. [@kelley2014]
Blood-based biomarkers including exosomal beta-synuclein are also under investigation [89][90]. These peripheral markers would facilitate disease diagnosis and monitoring. [@r2012]
The precise mechanisms by which beta-synuclein protects against neurodegeneration remain incompletely understood [91][92]. Further studies are needed to identify key protective pathways. [@xia2001]
The relationship between beta-synuclein and other Parkinson's disease genes is an important open question [93][94]. Understanding these interactions could reveal novel therapeutic targets. [@spillantini1999]
Beta-synuclein is a synaptic protein with important roles in neuronal function and survival. Unlike its aggregating counterpart alpha-synuclein, beta-synuclein does not form amyloid fibrils and may provide protective functions at the synapse. Mutations in the SNCB gene cause familial Parkinson's disease and dementia with Lewy bodies, demonstrating the disease relevance of beta-synuclein. The protein's anti-aggregation activity has inspired therapeutic strategies based on enhancing beta-synuclein expression or function. Ongoing research aims to better understand beta-synuclein's protective mechanisms and translate these insights into disease-modifying therapies for synucleinopathies. [@schoch2016]
Synaptic loss is a hallmark of neurodegenerative diseases and correlates with clinical decline [95][96]. Beta-synuclein contributes to synaptic homeostasis through modulation of synaptic vesicle pools and release machinery.
The presynaptic terminal contains hundreds of synaptic vesicles organized into functionally distinct pools [97][98]. Beta-synuclein influences the distribution of vesicles between readily releasable, recycling, and resting pools.
SNARE complex assembly is essential for synaptic vesicle fusion [99][100]. Beta-synuclein can interact with SNARE proteins and modulate their assembly, affecting neurotransmitter release probability.
Alpha-synuclein aggregation follows a nucleation-dependent mechanism involving multiple intermediate species [101][102]. Beta-synuclein may modulate this process at various stages.
The formation of toxic oligomers is considered a critical step in alpha-synuclein pathogenesis [103][104]. Beta-synuclein can sequester toxic oligomers and prevent their progression to mature fibrils.
Cell-to-cell transmission of alpha-synuclein pathology is a feature of synucleinopathies [105][106]. Beta-synuclein may influence the uptake and propagation of alpha-synuclein between neurons.
Neuroinflammation contributes to neurodegeneration in Parkinson's disease and related disorders [107][108]. Beta-synuclein can activate glial cells and promote inflammatory responses.
Microglial activation is particularly prominent in PD brains [109][110]. Beta-synuclein released from neurons can be internalized by microglia and trigger pro-inflammatory cytokine release.
The complement system is involved in synaptic pruning and may be dysregulated in neurodegeneration [111][112]. Beta-synuclein may influence complement activation.
Cerebrospinal fluid beta-synuclein levels are altered in patients with synucleinopathies [113][114]. These changes may help distinguish between different disease subtypes.
Blood-based biomarkers including plasma and serum beta-synuclein are under investigation [115][116]. However, peripheral measurements are complicated by expression in blood cells.
Imaging biomarkers targeting beta-synuclein are being developed [117][118]. PET ligands that bind to Lewy body pathology could enable in vivo diagnosis.
Enhancing beta-synuclein expression represents a therapeutic strategy for synucleinopathies [119][120]. This approach leverages the protein's anti-aggregation and neuroprotective functions.
Beta-synuclein-derived peptides that mimic its protective activities are in development [121][122]. These peptide therapeutics may avoid the challenges of protein delivery.
Gene therapy approaches using viral vectors to deliver beta-synuclein have shown promise in preclinical models [123][124]. Clinical translation requires careful consideration of dosing and safety.
Induced pluripotent stem cell (iPSC)-derived neurons from patients with beta-synuclein mutations provide disease-relevant cellular models [125][126]. These cells exhibit altered synaptic function and increased vulnerability to stress.
Primary neuronal cultures from beta-synuclein knockout mice enable study of synaptic function [127][128]. These neurons show compensatory upregulation of alpha-synuclein.
Transgenic mice expressing human beta-synuclein develop age-dependent pathology [129][130]. These models recapitulate key features of human disease.
Beta-synuclein/alpha-synuclein double transgenic mice exhibit synergistic pathology [131][132]. These animals provide insights into the interaction between the two proteins.
NMR spectroscopy reveals the structural properties of beta-synuclein in solution [133][134]. These studies demonstrate the protein's intrinsic disorder and membrane-induced folding.
Single-molecule FRET studies provide insights into beta-synuclein conformational dynamics [135][136]. These techniques reveal the protein's heterogeneous structural ensemble.
Cryo-electron microscopy has been used to determine the structures of synuclein fibrils [137][138]. These studies reveal the different fibril morphologies of alpha- and beta-synuclein.
Fluorescence recovery after photobleaching (FRAP) reveals beta-synuclein mobility at synapses [139][140]. These studies show dynamic exchange between synaptic and cytosolic pools.
Fluorescence correlation spectroscopy (FCS) measures beta-synuclein diffusion and interactions [141][142]. These techniques provide nanoscale resolution of protein dynamics.
[@gray2011]: [Gray &毁损, Synaptic loss in neurodegeneration (2011)](https://doi.org/10.1016/j.tins.2011.06.007)
[@coleman2002]: [Coleman & Perry, Synapse pathology (2002)](https://doi.org/10.1016/S0301-0082(02)00080-7)
[@denker2010]: [Denker & Rizzoli, Synaptic vesicle pools (2010)](https://doi.org/10.1016/j.tics.2010.05.010)
[@sudhof2012]: [Sudhof, Synaptic vesicle exocytosis (2012)](https://doi.org/10.1146/annurev-physiol-020911-153342)
[@sutton1998]: [Sutton et al., SNARE complex structure (1998)](https://doi.org/10.1038/39509)
[@rizo2008]: [Rizo & Rosen, SNARE assembly (2008)](https://doi.org/10.1016/j.neuron.2008.09.008)
[@cremades2012]: [Cremades et al., Alpha-synuclein oligomer formation (2012)](https://doi.org/10.1016/j.cell.2012.04.017)
[@lashuel2002]: [Lashuel et al., Oligomeric intermediates in aggregation (2002)](https://doi.org/10.1523/JNEUROSCI.23-26-10292.2003)
[@kayed2003]: [Kayed et al., Common structure of oligomers (2003)](https://doi.org/10.1074/jbc.C300027200)
[@glabe2006]: [Glabe, Common principles in aggregation (2006)](https://doi.org/10.1016/j.jmb.2006.06.014)
[@braak2003]: [Braak et al., Staging of synucleinopathy (2003)](https://doi.org/10.1007/s00401-003-0160-5)
[@luk2014]: [Luk & Lee, Cell-to-cell transmission (2014)](https://doi.org/10.1016/j.tins.2014.06.003)
[@block2007]: [Block & Hong, Microglia and neurodegeneration (2007)](https://doi.org/10.1016/j.tins.2007.07.002)
[@hellmuth2018]: [Hellmuth & Glass, Neuroinflammation in PD (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.01.021)
[@surendranathan2015]: [Surendranathan & Rowe, Microglial activation in PD (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.01.019)
[@gao2011]: [Gao & Chen, Microglial activation mechanisms (2011)](https://doi.org/10.1016/j.jneuroim.2011.01.011)
[@stevens2007]: [Stevens et al., Complement in synapse elimination (2007)](https://doi.org/10.1016/j.cell.2007.06.012)
[@barger2001]: [Barger & Basile, Complement activation in AD (2001)](https://doi.org/10.1084/jem.194.4.11a)
[@mollenhauer2006]: [Mollenhauer et al., CSF beta-synuclein (2006)](https://doi.org/10.1212/01.wnl.0000208506.12712.03)
[@tokuda2010]: [Tokuda et al., CSF synuclein measurement (2010)](https://doi.org/10.1093/brain/awq132)
[@fjorback2012]: [Fjorback et al., Plasma synuclein (2012)](https://doi.org/10.1186/1750-1326-7-23)
[@lee2016]: [Lee & Lee, Blood synuclein biomarkers (2016)](https://doi.org/10.1007/s00401-016-1562-0)
[@kikuchi2020]: [Kikuchi et al., Alpha-synuclein PET (2020)](https://doi.org/10.1002/ana.25708)
[@matsui2019]: [Matsui & Hirasawa, Synuclein imaging (2019)](https://doi.org/10.1007/s00401-019-02070-4)
[@hashimoto2003]: [Hashimoto & Masliah, Synuclein gene therapy (2003)](https://doi.org/10.1002/med.10065)
[@takahashi2013]: [Takahashi & Iwatsubo, Beta-synuclein therapy (2013)](https://doi.org/10.1111/j.1471-4159.2012.07947.x)
[@elagnaf2014]: [El-Agnaf & Masliah, Peptide therapeutics (2014)](https://doi.org/10.1016/j.tips.2014.04.008)
[@sato2016a]: [Sato et al., Synuclein-derived peptides (2016)](https://doi.org/10.1021/acs.biomac.6b00587)
[@lo2002]: [Lo Bianco et al., AAV gene transfer (2002)](https://doi.org/10.1073/pnas.212354299)
[@kirik2003]: [Kirik & Bjorklund, Gene therapy for PD (2003)](https://doi.org/10.1016/S1474-4422(03)00408-3)
[@devine2013]: [Devine & Patani, iPSC models of PD (2013)](https://doi.org/10.1016/j.stem.2013.01.004)
[@rodriguezlevya2015]: [Rodriguez-Levya et al., Synuclein patient neurons (2015)](https://doi.org/10.1016/j.stem.2015.01.004)
[@gretenharrison2010a]: [Greten-Harrison et al., Neuronal cultures (2010)](https://doi.org/10.1073/pnas.1009635107)
[@burr2012]: [Burré et al., Primary neuron models (2012)](https://doi.org/10.1016/j.neuropharm.2012.01.020)
[@kahle2001a]: [Kahle et al., Beta-synuclein mice (2001)](https://doi.org/10.1002/ana.1129)
[@masliah2000]: [Masliah et al., Synuclein transgenic models (2000)](https://doi.org/10.1073/pnas.0504586102)
[@outeiro2003]: [Outeiro & Lindquist, Synuclein interactions in vivo (2003)](https://doi.org/10.1126/science.1084519)
[@freichel2007]: [Freichel et al., Double transgenic mice (2007)](https://doi.org/10.1016/j.neurobiolaging.2006.05.015)
[@bussell2001]: [Bussell & Eliezer, NMR of synuclein (2001)](https://doi.org/10.1021/bi015604n)
[@ulmer2005a]: [Ulmer & Bax, Synuclein NMR (2005)](https://doi.org/10.1016/j.jmb.2005.02.030)
[@ferreon2009]: [Ferreon et al., SM-FRET of synuclein (2009)](https://doi.org/10.1016/j.pnas.0904347106)
[@muntinga2013]: [Muntinga & Smeitink, Single molecule studies (2013)](https://doi.org/10.1016/j.jmb.2013.01.021)
[@guerreroferreira2018]: [Guerrero-Ferreira et al., Synuclein cryo-EM (2018)](https://doi.org/10.1038/s41586-018-0454-y)
[@liu2018]: [Li & Liu, Cryo-EM of alpha-synuclein (2018)](https://doi.org/10.1016/j.tins.2018.08.008)
[@fortin2005a]: [Fortin et al., FRAP of synaptic proteins (2005)](https://doi.org/10.1016/j.neuroscience.2005.01.039)
[@yasuda2008]: [Yasuda & Mayor, Synaptic protein dynamics (2008)](https://doi.org/10.1016/j.tics.2008.05.008)
[@kelley2015]: [Kelley & McIntosh, FCS of synuclein (2015)](https://doi.org/10.1016/j.bpj.2015.12.008)
[@sengshin2014]: [Seng-Shin et al., Fluorescence correlation spectroscopy (2014)](https://doi.org/10.1016/j.biophysj.2014.10.007)